FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891458503> ?p ?o ?g. }

• W2891458503 endingPage "1037" @default.
• W2891458503 startingPage "1037" @default.
• W2891458503 abstract "1037 Background: MBC is incurable and managed with ongoing therapy. This study examined the incremental costs of chemotherapy-associated AEs in MBC. Methods: The PharMetrics Integrated Database (2000-2010) was used to identify MBC pts treated either 1 st or 2 nd line with a taxane (T) (paclitaxel or docetaxel) or capecitabine (C)-based regimen for ≥30 days (defined as a treatment episode (TE)). Incremental costs attributable to AEs were assessed by comparing costs incurred during TEs with and without AEs. AEs were identified using medical claims with a diagnosis for ≥1 event of interest (e.g., infections, fatigue, anemia, neutropenia). Pt characteristics were balanced between comparison groups (with and w/o AEs) using inverse probability weighting method. Incremental monthly costs due to AEs were estimated during the TEs and included the following cost components: inpt (IP), outpt (OP), emergency room (ER), other medical service, pharmacy costs (chemotherapy and other drugs), and total healthcare costs. Statistical comparisons were conducted using Wilcoxon tests. Results: 3,222 women (mean age=57) received a T or C as 1st or 2nd-line therapy for MBC. Of the 2,678 1st-line pts, 69.7% received T and 30.3% with C; average monthly total costs ranged from $9,159 to $10,298. AEs were commonly seen in pts treated with 1st-line T and C (94.6% and 83.7%). On average, the total monthly incremental cost associated with AEs was 38% higher ($3,547) for T and 9% higher ($854) for C. IP and other drug costs accounted for a majority of these costs. Of 1,084 2nd-line pts, 66% received T and 34% C, with average monthly total costs ranging from $5,950 to $12,979. 94.4% of T pts and 84% of C pts in the 2nd-line had an AE. The average total monthly incremental cost associated with AEs for T was $5,320 and $4,933 for C (69.5% and 82.9% higher vs pts w/o AEs). Pharmacy costs accounted for a majority of increased costs seen in pts with AEs treated with T; IP and OP accounted for a majority of these costs in pts treated with C. Conclusions: This is the 1 st study assessing costs associated with AEs for tx of mBC. AEs are associated with a substantial economic burden that is mainly explained by increased IP, OP, and pharmacy costs." @default.
• W2891458503 created "2018-09-27" @default.
• W2891458503 creator A5032187510 @default.
• W2891458503 creator A5033092533 @default.
• W2891458503 creator A5035592082 @default.
• W2891458503 creator A5041026389 @default.
• W2891458503 creator A5045788834 @default.
• W2891458503 creator A5068059897 @default.
• W2891458503 creator A5072015843 @default.
• W2891458503 creator A5089194015 @default.
• W2891458503 date "2012-05-20" @default.
• W2891458503 modified "2023-09-26" @default.
• W2891458503 title "Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies." @default.
• W2891458503 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.1037" @default.
• W2891458503 hasPublicationYear "2012" @default.
• W2891458503 type Work @default.
• W2891458503 sameAs 2891458503 @default.
• W2891458503 citedByCount "1" @default.
• W2891458503 countsByYear W28914585032012 @default.
• W2891458503 crossrefType "journal-article" @default.
• W2891458503 hasAuthorship W2891458503A5032187510 @default.
• W2891458503 hasAuthorship W2891458503A5033092533 @default.
• W2891458503 hasAuthorship W2891458503A5035592082 @default.
• W2891458503 hasAuthorship W2891458503A5041026389 @default.
• W2891458503 hasAuthorship W2891458503A5045788834 @default.
• W2891458503 hasAuthorship W2891458503A5068059897 @default.
• W2891458503 hasAuthorship W2891458503A5072015843 @default.
• W2891458503 hasAuthorship W2891458503A5089194015 @default.
• W2891458503 hasConcept C121608353 @default.
• W2891458503 hasConcept C126322002 @default.
• W2891458503 hasConcept C143998085 @default.
• W2891458503 hasConcept C197934379 @default.
• W2891458503 hasConcept C2775930923 @default.
• W2891458503 hasConcept C530470458 @default.
• W2891458503 hasConcept C71924100 @default.
• W2891458503 hasConceptScore W2891458503C121608353 @default.
• W2891458503 hasConceptScore W2891458503C126322002 @default.
• W2891458503 hasConceptScore W2891458503C143998085 @default.
• W2891458503 hasConceptScore W2891458503C197934379 @default.
• W2891458503 hasConceptScore W2891458503C2775930923 @default.
• W2891458503 hasConceptScore W2891458503C530470458 @default.
• W2891458503 hasConceptScore W2891458503C71924100 @default.
• W2891458503 hasIssue "15_suppl" @default.
• W2891458503 hasLocation W28914585031 @default.
• W2891458503 hasOpenAccess W2891458503 @default.
• W2891458503 hasPrimaryLocation W28914585031 @default.
• W2891458503 hasRelatedWork W1980656908 @default.
• W2891458503 hasRelatedWork W2001477191 @default.
• W2891458503 hasRelatedWork W2061467078 @default.
• W2891458503 hasRelatedWork W2076253404 @default.
• W2891458503 hasRelatedWork W2130207808 @default.
• W2891458503 hasRelatedWork W2266510244 @default.
• W2891458503 hasRelatedWork W2535200940 @default.
• W2891458503 hasRelatedWork W2622263925 @default.
• W2891458503 hasRelatedWork W2737206118 @default.
• W2891458503 hasRelatedWork W4253360580 @default.
• W2891458503 hasVolume "30" @default.
• W2891458503 isParatext "false" @default.
• W2891458503 isRetracted "false" @default.
• W2891458503 magId "2891458503" @default.
• W2891458503 workType "article" @default.